Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity

Table 2

	Case A	Case B	Case C
Diagnosis	t-AML*	AML	ALL
Age at first diagnosis	21	29	32
Date of first diagnosis	04/2007	05/2005	11/2010
Course of treatment
Induction	Cytarabine + idarubicin/HAM	Sequential HAM	None
(1) Allogeneic HSCT	08/07: allogeneic HSCT (MUD)	07/05: allogeneic HSCT (MRD)
	02/12: Relapse incl. chloroma/CNS	01/09: relapse
Salvage therapies	Clofarabine	03/2009 Stem cell boost + GM-CSF
		07/09 Relapse; incl. chloroma
		Cytarabine + gemtuzumab/ozogamicin
(2) Allogeneic HSCT	05/12: HLA haploidentical HSCT (sister)	08/09: HLA haploidentical HSCT + G-CSF (father)
Status at testing	03/13: Relapse	07/10: Relapse; incl. chloroma,; immunotherapy	First diagnosis

∗Therapy related AML after 8x BEACOPP for Hodgkin’s disease.
Abbreviations: AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, MUD: matched unrelated donor, MRD: matched related donor, G-CSF/GM-CSF: granulocyte/granulocyte macrophage colony-stimulating factor, HAM: high dosed cytarabin/mitoxantron, CNS: central nervous system involvement.